Repligen Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Tony Hunt
Chief executive officer
US$7.9m
Total compensation
| CEO salary percentage | 11.1% |
| CEO tenure | 9yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.7yrs |
| Board average tenure | 8.2yrs |
Recent management updates
Recent updates
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Apr 30
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Apr 15At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?
Feb 13Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Jan 08Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price
Dec 19What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?
Nov 01Is Repligen (NASDAQ:RGEN) Using Too Much Debt?
Oct 17Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?
Sep 29Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade
Aug 09Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?
Jul 17Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?
Jul 03With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case
Jun 19Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)
May 23Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Apr 11Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?
Mar 28We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease
Mar 08Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Feb 20Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Jan 10Should You Think About Buying Repligen Corporation (NASDAQ:RGEN) Now?
Dec 28Is Repligen (NASDAQ:RGEN) A Risky Investment?
Oct 03Repligen: Now Best Biotech Nearby Cap-Gain Prospect
Sep 27Repligen partners with DRS daylight solutions
Sep 19When Should You Buy Repligen Corporation (NASDAQ:RGEN)?
Sep 19Do Repligen's (NASDAQ:RGEN) Earnings Warrant Your Attention?
Aug 23Repligen briefly turns positive after report of rejected takeover offer
Aug 11Calculating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Aug 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$15m |
| Dec 31 2023 | US$8m | US$880k | US$42m |
| Sep 30 2023 | n/a | n/a | US$116m |
| Jun 30 2023 | n/a | n/a | US$138m |
| Mar 31 2023 | n/a | n/a | US$168m |
| Dec 31 2022 | US$8m | US$800k | US$186m |
| Sep 30 2022 | n/a | n/a | US$166m |
| Jun 30 2022 | n/a | n/a | US$159m |
| Mar 31 2022 | n/a | n/a | US$146m |
| Dec 31 2021 | US$8m | US$761k | US$128m |
| Sep 30 2021 | n/a | n/a | US$119m |
| Jun 30 2021 | n/a | n/a | US$100m |
| Mar 31 2021 | n/a | n/a | US$80m |
| Dec 31 2020 | US$5m | US$725k | US$60m |
| Sep 30 2020 | n/a | n/a | US$44m |
| Jun 30 2020 | n/a | n/a | US$31m |
| Mar 31 2020 | n/a | n/a | US$23m |
| Dec 31 2019 | US$4m | US$685k | US$21m |
| Sep 30 2019 | n/a | n/a | US$23m |
| Jun 30 2019 | n/a | n/a | US$27m |
| Mar 31 2019 | n/a | n/a | US$21m |
| Dec 31 2018 | US$14m | US$600k | US$17m |
| Sep 30 2018 | n/a | n/a | US$23m |
| Jun 30 2018 | n/a | n/a | US$23m |
| Mar 31 2018 | n/a | n/a | US$29m |
| Dec 31 2017 | US$3m | US$550k | US$28m |
Compensation vs Market: Tony's total compensation ($USD7.93M) is about average for companies of similar size in the US market ($USD8.43M).
Compensation vs Earnings: Tony's compensation has been consistent with company performance over the past year.
CEO
Tony Hunt (59 yo)
9yrs
Tenure
US$7,929,275
Compensation
Mr. Anthony J. Hunt, also known as Tony, serves as Director at 908 Devices Inc. since March 2, 2022. He has been the Chief Executive Officer of Repligen Corporation since May 21, 2015 and served as its Pre...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 9yrs | US$7.93m | 0.18% $ 16.3m | |
| President & Chief Commercial Officer | less than a year | US$5.45m | no data | |
| CFO & Chief Compliance Officer | less than a year | US$2.03m | no data | |
| Chief Operating Officer | 4.2yrs | US$3.74m | 0.037% $ 3.4m | |
| Senior Vice President of Filtration & Chromatography | 3.8yrs | US$1.66m | 0.050% $ 4.6m | |
| Senior Vice President of Research & Development | 7.6yrs | US$1.66m | 0.029% $ 2.7m | |
| Chief Information Officer | no data | no data | no data | |
| Global Head of Investor Relations | no data | no data | no data | |
| General Counsel & Global Head of Legal | no data | no data | no data | |
| Senior Vice President of Global Marketing | no data | no data | no data | |
| VP & Global Head of Sales | 1.6yrs | no data | no data | |
| Vice President of Human Resources | 1.3yrs | no data | no data |
2.7yrs
Average Tenure
57yo
Average Age
Experienced Management: RGEN's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 9yrs | US$7.93m | 0.18% $ 16.3m | |
| Independent Director | 8.6yrs | US$322.84k | 0.012% $ 1.1m | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
| Independent Director | 1.3yrs | US$453.50k | 0.0029% $ 269.3k | |
| Independent Chairperson of the Board | 18.7yrs | US$431.12k | 0.16% $ 14.4m | |
| Independent Director | 3.9yrs | US$287.84k | 0.0038% $ 350.1k | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
| Member of Scientific Advisory Board & Independent Director | 8.2yrs | US$282.84k | 0.00096% $ 89.2k | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
| Independent Director | 4.2yrs | US$287.84k | 0.0030% $ 275.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 9.9yrs | US$307.84k | 0.0037% $ 346.4k |
8.2yrs
Average Tenure
63yo
Average Age
Experienced Board: RGEN's board of directors are considered experienced (8.2 years average tenure).